W. L. Gore & Associates Inc. has received U.S. Food and Drug Administraion (FDA) approval for the new large diameter 35 mm trunk-ipsilateral leg and 36 mm aortic extender components, as well as the lower profile 31 mm diameter trunk-ipsilateral leg and 32 mm aortic extender components of the Gore Excluder AAA Endoprosthesis. The new components provide physicians with a proven and durable endovascular option to treat abdominal aortic aneurysms (AAAs).

Tyrx Inc. has received a license from Health Canada to market its new AigisRx R Fully Resorbable Antibacterial Envelope technology with implantable electronic devices (IEDs). The AigisRx R Antibacterial Envelope is specifically designed to stabilize IEDs while also releasing antimicrobial agents to help provide protection from microbial colonization of the device during surgical implantation. Tyrx is the leader in the commercialization of implantable medical devices intended to help reduce surgical site infections.

The FREEDOM trial, the first long-term, comparative study of its kind exclusively for patients with diabetes and advanced multivessel coronary artery disease (CAD) revealed that diabetics with CAD live longer and are less likely to suffer a non-fatal heart attack when treated with bypass surgery instead of drug-eluting stents (DES), tiny, medicine-coated mesh tubes that prop open clogged arteries.

Samsung Electronics America Inc. announced the Samsung Ugeo H60, the first ultrasound system integrating Samsung technology and design introduced to the U.S. medical imaging market. The Samsung Ugeo H60 ensures superior imaging performance and a sleek design that provides users with a fast, accurate and intuitive ultrasound experience.

Angiotech Pharmaceuticals Inc. announced that it entered into a definitive agreement to sell certain of its subsidiaries, comprising Angiotech's interventional products business, to Argon Medical Devices Inc., a portfolio company of RoundTable Healthcare Partners, for $362.5 million in cash consideration. Angiotech expects the transaction will close prior to the end of April 2013.

Archimedes IndiGo — the physician and patient decision-support tool created by Archimedes, Inc. — was chosen last summer as the risk-assessment engine for the new $100,000 mobile app challenge sponsored by the Office of the National Coordinator (ONC). As part of the U.S. Department of Health and Human Services' Million Hearts "Risk Check Challenge," the ONC invited developers to create a mobile app that would help consumers take a heart-health risk assessment, direct them to health-screening locations in their community and use the results to work with their doctor to develop a plan for improving their heart health.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now